Nucynta FDA Approval Year
Nucynta (tapentadol) was approved by the FDA in November 2008 for the treatment of moderate-to-severe acute pain in adults. 1, 2
Initial Approval Details
The immediate-release formulation of tapentadol was the first new centrally acting analgesic approved by the FDA in 2008, representing a novel class of analgesics with dual mechanism of action 2
The drug was classified as a Schedule II controlled substance (C-II) at the time of its initial approval 1
Subsequent Formulation Approvals
Extended-release tapentadol (Nucynta ER) was subsequently approved in August 2011 for chronic pain management requiring continuous, around-the-clock opioid treatment 3, 4
The extended-release formulation was later approved for treatment of chronic painful diabetic neuropathy 5